Tonix Pharmaceuticals Welcomes Joseph Hand as New Executive VP
Tonix Pharmaceuticals Appoints Joseph Hand, Esq.
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has made a significant move by appointing Joseph Hand, Esq., to the role of General Counsel and Executive Vice President of Operations. This occasion marks an important transition for the company, as Mr. Hand brings over two decades of extensive legal and business leadership experience, particularly within the biopharmaceutical sector.
Mr. Hand's Impressive Background
Mr. Hand has been a key figure in the biopharmaceutical industry, with a remarkable tenure at Celgene Corporation where he spent nearly ten years in various senior executive roles. His extensive roles included participating in Celgene's Executive Committee, where he played a critical role in the integration of Celgene into Bristol Myers Squibb and participated in the successful divestiture of Otezla to Amgen. His experience at Celgene uniquely positions him to guide Tonix Pharmaceuticals at this pivotal moment, particularly as the company prepares for the potential approval of TNX-102 SL, a treatment aimed at managing fibromyalgia.
Comments from Leadership
Seth Lederman, M.D., the Chief Executive Officer of Tonix Pharmaceuticals, expressed confidence in the new appointment. "Joe’s strong track record of delivering company growth, driving transformative initiatives, and negotiating complex transactions makes him an important strategic addition to the Tonix team at a pivotal inflection point in the Company’s history," he remarked. He emphasized that Mr. Hand’s broad expertise and commitment to operational excellence perfectly align with the company’s mission, particularly as they prepare for the upcoming launch of TNX-102 SL upon receiving FDA marketing authorization.
Experience Beyond Celgene
Before joining Tonix, Mr. Hand served as Chief Administrative Officer at Phathom Pharmaceuticals, where he spearheaded efforts to enhance talent acquisition, leading to the hiring of over 300 employees across various functions while establishing a robust commercial sales force. Mr. Hand began his career practicing litigation at the prestigious international law firm of Jones Day. He holds a Bachelor of Business Administration from the University of Notre Dame and a Juris Doctor degree from New York University School of Law. His diverse experiences have equipped him with a keen understanding of the complexities involved in legal, business, and operational functions, making him an ideal fit for Tonix Pharmaceuticals.
Strategic Focus for Tonix Pharmaceuticals
Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company dedicated to creating effective treatments for pain management and addressing significant public health challenges through innovative vaccines. The company is particularly focused on advancing the development of TNX-102 SL, a candidate designed for fibromyalgia management. This initiative follows the submission of a New Drug Application (NDA) underpinned by promising results from two statistically significant Phase 3 studies. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date for making a marketing decision.
Furthermore, TNX-102 SL has earned Fast Track designation, highlighting its potential importance in this therapeutic area. Tonix is also exploring the treatment of acute stress reactions and disorders through ongoing studies, demonstrating their commitment to addressing a range of mental health challenges alongside their physical health therapies.
Expanding the Health Landscape
Furthermore, Tonix Pharmaceuticals is actively expanding its immunology portfolio to tackle significant health issues, including organ transplant rejection, autoimmunity, and cancer. One of their noteworthy candidates is TNX-1500, an Fc-modified humanized monoclonal antibody aimed at preventing allograft rejection and treating autoimmune conditions. Additionally, Tonix is developing an innovative vaccine for mpox, TNX-801.
The company has also recently engaged in a significant contract with the U.S. Department of Defense’s Defense Threat Reduction Agency (DTRA) valued at $34 million over five years, focused on developing TNX-4200, a small-molecule antiviral agent aimed at improving military readiness in the face of biological threats.
Tonix Medicines: Delivering Treatments
Tonix owns and operates a cutting-edge infectious disease research facility located in Frederick, Maryland. The company’s commercial subsidiary, Tonix Medicines, markets Zembrace SymTouch and Tosymra, two essential treatments for acute migraine in adults. By prioritizing research and development, Tonix Pharmaceuticals is committed to providing meaningful therapies that address unmet medical needs in various patient populations.
Frequently Asked Questions
Who is Joseph Hand?
Joseph Hand is the newly appointed General Counsel and Executive Vice President of Operations at Tonix Pharmaceuticals, bringing over 20 years of experience in the biopharmaceutical industry.
What are the key responsibilities of Joseph Hand at Tonix?
His responsibilities include overseeing legal affairs, business development, human resources, and the company’s operational strategies, particularly as it prepares for TNX-102 SL's market launch.
What is TNX-102 SL?
TNX-102 SL is a product candidate under development by Tonix Pharmaceuticals for the management of fibromyalgia, with a recent NDA submitted to the FDA.
What is Tonix Pharmaceuticals' focus?
Tonix Pharmaceuticals focuses on transforming therapies for pain management, central nervous system disorders, and public health challenges through innovative vaccines and treatments.
How does Tonix Pharmaceuticals engage with the U.S. Department of Defense?
Tonix has a contract with the U.S. DoD’s Defense Threat Reduction Agency for developing antiviral agents aimed at improving military personnel's readiness against biological threats.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
